Salts of cyclohexane derivatives
The development of cyclohexane derivative salts, particularly maleate, phosphate, and hydrochloride, addresses stability and bioavailability issues, enhancing the efficacy of cyclohexane derivatives for mental disorder treatment.
Patent Information
- Application Number
- JP2021510970
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-08-30
- Filing Date
- 2019-08-13
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2039-08-13
AI Technical Summary
Existing cyclohexane derivatives, such as compound 1 with the structural formula of formula I, face challenges in stability, hygroscopicity, and pharmacokinetic properties during formulation and storage, necessitating the development of more stable and bioavailable forms.
The development of salts of cyclohexane derivatives, specifically maleate, phosphate, sulfate, and hydrochloride salts, which exhibit increased stability, reduced hygroscopicity, and improved pharmacokinetic properties, including longer half-life and higher bioavailability.
The salts demonstrate high crystallinity, low weight loss, unique endothermic signals in DSC, and enhanced bioavailability, offering improved efficacy and stability for treating mental disorders.
Smart Images

Figure 0007581182000028 
Figure 0007581182000029 
Figure 0007581182000030
Abstract
Description
[Technical field]
[0001] The present invention relates to the field of medicinal chemistry, and more particularly to salts of cyclohexane derivatives for treating mental disorders and methods for preparing the same. [Background technology]
[0002] The present inventors have previously disclosed compound 1 of formula I in CN106518841A, whose chemical name is N'-[trans-4-[2-[4-(benzo[b]thiophen-7-yl)piperazin-1-yl]ethyl]cyclohexyl]-N,N-dimethylurea Cyclohexane derivatives as shown in the structural formula of formula I: N'-[trans-4-[2-[4-(benzo[b]thiophen-7-yl)piperazin-1-yl]ethyl]cyclohexyl]-N,N-dimethylurea It has D2 / D3 antagonistic activity, 5-hydroxytryptamine absorption inhibitory activity and antipsychotic activity, and is particularly highly selective for the D3 / D2 receptors with minimal side effects. [ka]
[0003] To enhance the stability of the compound during formulation and storage and to improve its pharmacokinetic properties, better forms of the compound are needed, such as salts of the compound of formula I. Summary of the Invention [Problem to be solved by the invention]
[0004] The present inventor has conducted extensive research based on the existing compound of formula I and developed the following salt of the compound of formula I. Compound I has improved stability, reduced hygroscopicity, and in vivo experiments have shown that it has a long in vivo half-life, high in vivo bioavailability, and small individual variation in vivo. Specifically, the present invention provides the following technical solutions: [Means for solving the problem]
[0005] In a first aspect of the present invention, a cyclohexane derivative according to formula I is provided: N'-[trans-4-[2-[4-(benzo[b]thiophen-7-yl)piperazin-1-yl]ethyl]cyclohexyl]-N,N-dimethylurea is provided, said salt comprising an anion, said anion being maleate. [ka]
[0006] In one embodiment, in the maleate salt of the invention, the stoichiometric ratio of compound of formula I to anion is 1:1.
[0007] In one embodiment, the maleate salt of the compound of formula I of the present invention has the chemical formula shown in formula II. [ka]
[0008] In one embodiment, the maleate salt of the present invention has a powder X-ray diffraction pattern expressed in 2θ angles using CuKα radiation of at least 11.804°±0.2°, 12.703°±0.2°, 13.493°±0.2°, 14.495°±0.2°, 15.096°±0.2°, 17.108°±0.2°, 19.104°±0.2°, 19.655°±0.2°, 20.023°±0.2°, 21.611°±0.2°, and 24.088°±0.2°. Diffraction peaks are observed at 0.2°, and preferably at least 11.804°±0.02°, 12.703°±0.02°, 13.493°±0.02°, 14.495°±0.02°, 15.096°±0.02°, 17.108°±0.02°, 19.104°±0.02°, 19.655°±0.02°, 20.023°±0.02°, 21.611°±0.02° and 24.088°±0.02°.
[0009] In one embodiment, the maleate salt of the present invention further exhibits diffraction peaks at 2θ values of 7.246°±0.2°, 17.567°±0.2°, 18.794°±0.2°, 20.395°±0.2°, 21.030°±0.2°, 22.496°±0.2°, 24.867°±0.2°, and 26.412°±0.2°, and preferably further exhibits diffraction peaks at 2θ values of 7.246°±0.02°, 17.567°±0.02°, 18.794°±0.02°, 20.395°±0.02°, 21.030°±0.02°, 22.496°±0.02°, 24.867°±0.02°, and 26.412°±0.02°.
[0010] In one embodiment, the maleate salt of the present invention further exhibits diffraction peaks at 2θ values of 11.045°±0.2°, 22.997°±0.2°, 25.336°±0.2°, 27.786°±0.2°, 28.292°±0.2°, 28.914°±0.2°, 29.804°±0.2°, 30.770°±0.2°, 31.628°±0.2°, and 33.952°±0.2°. and preferably further diffraction peaks are observed at 2θ values of 11.045°±0.02°, 22.997°±0.02°, 25.336°±0.02°, 27.786°±0.02°, 28.292°±0.02°, 28.914°±0.02°, 29.804°±0.02°, 30.770°±0.02°, 31.628°±0.02° and 33.952°±0.02°.
[0011] In one embodiment, the XRPD pattern of the maleate salt of the present invention is shown in FIG. 5A.
[0012] In one embodiment, DSC analysis of the maleate salt of the present invention shows an endothermic peak at 191.8°C.
[0013] In one embodiment, the DSC curve of the maleate salt of the present invention is as shown in FIG. 5B.
[0014] In one embodiment, TGA analysis of the maleate salt of the present invention shows a weight loss of 0.41% at 150°C.
[0015] In one embodiment, the TGA curve of the maleate salt of the present invention is shown in FIG. 5C.
[0016] The present invention further provides a process for preparing a maleate salt of the compound of formula I, comprising the step of reacting the compound of formula I with maleic acid in an organic solvent to obtain the maleate salt of the compound of formula I.
[0017] In one embodiment, in the maleate salt of the present invention, the reacting molar ratio of the compound of formula I to maleic acid is 1:1 to 1:2, preferably, the molar ratio is 1:1 to 1:1.1.
[0018] In one embodiment, the organic solvent is selected from isopropanol, acetone, ethyl acetate, acetonitrile, toluene, or a mixture of two or more thereof.
[0019] The present invention further provides a pharmaceutical composition for treating or ameliorating schizophrenia, mental retardation, mental disorder, mental retardation, mood disorder, bipolar disorder, depression, phobia, obsessive-compulsive disorder, anxiety disorder or cognitive impairment, comprising the maleate salt and a pharmaceutical excipient.
[0020] The maleate salt of the compound of formula I of the present invention has high crystallinity, small weight loss in TGA, a unique high endothermic signal in DSC, and is low hygroscopic, highly stable, and can be stored and transported for a long time, thereby reducing the production cost. In addition, it has high bioavailability and a long half-life in in vivo experiments, and is therefore a preferred salt form of the compound of formula I.
[0021] In a second aspect of the present invention, a cyclohexane derivative according to formula I is provided: N'-[trans-4-[2-[4-(benzo[b]thiophen-7-yl)piperazin-1-yl]ethyl]cyclohexyl]-N,N-dimethylurea is provided, said salt comprising an anion, said anion being a phosphate ion. [ka]
[0022] In one embodiment, in the phosphate salts of the invention, the stoichiometric ratio of compound of formula I to anion is 1:1.
[0023] In one embodiment, the chemical formula of the phosphate of the compound of formula I of the present invention is as shown in formula II-2. [ka]
[0024] In one embodiment, the phosphate of the present invention has a powder X-ray diffraction pattern expressed in 2θ angles using CuKα radiation, which shows diffraction peaks at least at 13.986°±0.2°, 15.241°±0.2°, 15.844°±0.2°, 18.154°±0.2°, 21.005°±0.2°, 21.241°±0.2° and 21.811°±0.2°, preferably at least 13.986°±0.02°, 15.241°±0.02°, 15.844°±0.02°, 18.154°±0.02°, 21.005°±0.02°, 21.241°±0.02° and 21.811°±0.02°.
[0025] In one embodiment, the phosphate salt of the present invention further exhibits diffraction peaks at 2θ values of 6.794°±0.2°, 9.973°±0.2°, 19.990°±0.2°, 24.450°±0.2°, 26.019°±0.2°, 27.309°±0.2°, 30.710°±0.2°, 32.056°±0.2°, 35.718°±0.2° and 36.401°±0.2°; Preferably, further diffraction peaks are observed at 2θ values of 6.794°±0.02°, 9.973°±0.02°, 19.990°±0.02°, 24.450°±0.02°, 26.019°±0.02°, 27.309°±0.02°, 30.710°±0.02°, 32.056°±0.02°, 35.718°±0.02° and 36.401°±0.02°.
[0026] In one embodiment, the XRPD pattern of a phosphate salt of the present invention is as shown in FIG. 4A.
[0027] In one embodiment, DSC analysis of the phosphate salt of the present invention shows an endothermic peak at 213.9°C.
[0028] In one embodiment, the DSC curve of the phosphate salt of the present invention is as shown in FIG. 4B.
[0029] In one embodiment, TGA analysis of the phosphate salt of the present invention shows a weight loss of 0.7% at 150°C.
[0030] In one embodiment, the TGA curve of the phosphate salt of the present invention is shown in FIG. 4C.
[0031] The present invention further provides a process for preparing a phosphate salt of a compound of formula I, comprising reacting said compound of formula I with phosphoric acid in an organic solvent to obtain the phosphate salt of the compound of formula I.
[0032] In one embodiment, the reacting molar ratio of the compound of formula I to phosphoric acid is 1:1 to 1:2, preferably, the molar ratio is 1:1 to 1:1.1.
[0033] In one embodiment, the organic solvent is selected from isopropanol, acetone, ethyl acetate, acetonitrile, toluene, or a mixture of two or more thereof.
[0034] The present invention further provides a pharmaceutical composition for treating or ameliorating schizophrenia, mental retardation, mental disorder, mental retardation, mood disorder, bipolar disorder, depression, phobia, obsessive-compulsive disorder, anxiety disorder or cognitive impairment disease, comprising the above phosphate and a pharmaceutical excipient.
[0035] The phosphate salt of the compound of formula I of the present invention has high crystallinity, low weight loss in TGA, a unique high endothermic signal in DSC, high bioavailability and long half-life in in vivo experiments, and has been found to be the preferred salt form of the compound of formula I.
[0036] In a third aspect of the present invention, there is provided a cyclohexane derivative as shown in formula I: N'-[trans-4-[2-[4-(benzo[b]thiophen-7-yl)piperazin-1-yl]ethyl]cyclohexyl]-N,N-dimethylurea is provided, said salt comprising an anion, said anion being a sulfate ion. [ka]
[0037] In one embodiment, in the sulfate salt of the invention, the stoichiometric ratio of compound of formula I to anion is 1:1.
[0038] In one embodiment, the chemical formula of the sulfate salt of the present invention is as shown in Formula II-3. [ka]
[0039] In one embodiment, the sulfate salt of the present invention has a powder X-ray diffraction pattern expressed in 2θ angles using CuKα radiation of at least 6.719°±0.2°, 15.927°±0.2°, 17.257°±0.2°, 17.781°±0.2°, 18.294°±0.2°, 18.863°±0.2°, 21.464°±0.2°, 21.711°±0.2°, and 23.806°±0.2°. Diffraction peaks are observed at 6.719°±0.02°, 15.927°±0.02°, 17.257°±0.02°, 17.781°±0.02°, 18.294°±0.02°, 18.863°±0.02°, 21.464°±0.02°, 21.711°±0.02° and 23.806°±0.02°.
[0040] In one embodiment, the sulfate salt of the present invention further exhibits diffraction peaks at 2θ values of 9.858°±0.2°, 14.437°±0.2°, 15.240°±0.2°, 20.792°±0.2°, 23.204°±0.2°, and 27.023°±0.2°, and preferably further exhibits diffraction peaks at 2θ values of 9.858°±0.02°, 14.437°±0.02°, 15.240°±0.02°, 20.792°±0.02°, 23.204°±0.02°, and 27.023°±0.02°.
[0041] In one embodiment, the sulfate salts of the invention may further have 2θ values of 7.195°±0.2°, 7.947°±0.2°, 12.610°±0.2°, 13.414°±0.2°, 14.823°±0.2°, 20.187°±0.2°, 22.207°±0.2°, 22.741°±0.2°, 24.552°±0.2°, 25.02°±0.2°, 26.01°±0.2°, 27.01°±0.2°, 28.01°±0.2°, 29.01°±0.2°, 30.01°±0.2°, 31.01°±0.2°, 32.01°±0.2°, 33.01°±0.2°, 34.01°±0.2°, 35.01°±0.2°, 36.01°±0.2°, 37.01°±0.2°, 38.01°±0.2°, 39.01°±0.2°, 40.01°±0.2°, 41.01°±0.2°, 42.01°±0.2°, 43.01°±0.2°, 44.01°±0.2°, 45.01°±0.2°, 46.01°±0.2°, 47.01°±0.2°, 48.01°±0.2°, 49.01°±0.2°, 50.01°±0.2°, 51.01°±0.2°, 52.01°±0.2°, 53. , 25.532°±0.2°, 26.631°±0.2°, 27.515°±0.2°, 28.190°±0.2°, 28.563°±0.2°, 29.829°±0.2°, 32.993°±0.2°, 34.360°±0.2° and 36.462°±0.2°, preferably , and further 2θ values of 7.195°±0.02°, 7.947°±0.02°, 12.610°±0.02°, 13.414°±0.02°, 14.823°±0.02°, 20.187°±0.02°, 22.207°±0.02°, 22.741°±0.02°, 24.552°±0.02°, and 25.5 Diffraction peaks are observed at 32°±0.02°, 26.631°±0.02°, 27.515°±0.02°, 28.190°±0.02°, 28.563°±0.02°, 29.829°±0.02°, 32.993°±0.02°, 34.360°±0.02° and 36.462°±0.02°.
[0042] In one embodiment, the XRPD pattern of the Sulfate Salt of the present invention is shown in FIG. 3A.
[0043] In one embodiment, DSC analysis of the Sulfate Salt of the present invention shows an endothermic peak at 195.1°C.
[0044] In one embodiment, the DSC curve of the Sulfate Salt of the present invention is as shown in FIG. 3B.
[0045] In one embodiment, TGA analysis of the sulfate salt of the present invention shows a weight loss of 0.43% at 150°C.
[0046] In one embodiment, the TGA curve of the Sulfate Salt of the present invention is shown in FIG. 3C.
[0047] The present invention further provides a process for preparing a sulfate salt of a compound of formula I, comprising reacting a compound of formula I with sulfuric acid in an organic solvent to obtain the sulfate salt of the compound of formula I.
[0048] In one embodiment, the reacting molar ratio of the compound of formula I to sulfuric acid is 1:1 to 1:2, preferably, the molar ratio is 1:1 to 1:1.1.
[0049] In one embodiment, the organic solvent is selected from isopropanol, ethyl acetate, acetonitrile, toluene, or a mixture of two or more thereof.
[0050] The present invention further provides a pharmaceutical composition for treating or ameliorating schizophrenia, mental retardation, mental disorder, mental retardation, mood disorder, bipolar disorder, depression, phobia, obsessive-compulsive disorder, anxiety disorder or cognitive impairment disease, comprising the sulfate salt and a pharmaceutical excipient.
[0051] The sulfate salt of the compound of formula I of the present invention has high crystallinity, low weight loss in TGA, a unique high endothermic signal in DSC, and has been shown to have fast onset and high bioavailability in vivo.
[0052] In a fourth aspect of the present invention, N'-[trans-4-[2-[4-(benzo[b]thiophen-7-yl)piperazin-1-yl]ethyl]cyclohexyl]-N,N-dimethylurea is provided, said salt comprising an anion, said anion being chloride. [ka]
[0053] In one embodiment, in the hydrochloride salt of the invention, the stoichiometric ratio of the compound of formula I to the anion is 1:1.
[0054] In one embodiment, the chemical formula of the hydrochloride salt of the present invention is as shown in Formula II-4. [ka]
[0055] In one embodiment, the hydrochloride salt of the present invention has a powder X-ray diffraction pattern using CuKα radiation, expressed in 2θ angles of at least 4.576°±0.2°, 10.982°±0.2°, 13.040°±0.2°, 13.738°±0.2°, 15.800°±0.2°, 16.914°±0.2°, 18.339°±0.2°, 19.119°±0.2°, 19.746°±0.2°, 20.029°±0.2°, 20.682°±0.2°, and 23.570°±0.2°. Diffraction peaks are observed at 2°, and preferably at least 4.576°±0.02°, 10.982°±0.02°, 13.040°±0.02°, 13.738°±0.02°, 15.800°±0.02°, 16.914°±0.02°, 18.339°±0.02°, 19.119°±0.02°, 19.746°±0.02°, 20.029°±0.02°, 20.682°±0.02° and 23.570°±0.02°.
[0056] In one embodiment, the hydrochloride salt of the invention further exhibits diffraction peaks at 2θ values of 9.123°±0.2°, 11.903°±0.2°, 12.216°±0.2°, 15.024°±0.2°, 17.370°±0.2°, 21.802°±0.2°, 22.151°±0.2°, 22.947°±0.2°, 24.581°±0.2°, 24.984°±0.2°, 25.586°±0.2°, 26.251°±0.2°, 26.533°±0.2°, 27.495°±0.2°, 30.408°±0.2° and 32.725°±0.2°, preferably at 2θ values of 9.123°±0.2°, 11.903°±0.2°, 12.216°±0.2°, 15.024°±0.2°, 17.370°±0.2°, 21.802°±0.2°, 22.151°±0.2°, 22.947°±0.2°, 24.581°±0.2°, 24.984°±0.2°, 25.586°±0.2°, 26.251°±0.2°, 26.533°±0.2°, 27.495°±0.2°, 30.408°±0.2° and 32.725°±0.2°. further show diffraction peaks at 2θ values of 9.123°±0.02°, 11.903°±0.02°, 12.216°±0.02°, 15.024°±0.02°, 17.370°±0.02°, 21.802°±0.02°, 22.151°±0.02°, 22.947°±0.02°, 24.581°±0.02°, 24.984°±0.02°, 25.586°±0.02°, 26.251°±0.02°, 26.533°±0.02°, 27.495°±0.02°, 30.408°±0.02°, and 32.725°±0.02°.
[0057] In one embodiment, the XRPD pattern of the hydrochloride salt of the present invention is shown in FIG. 2A.
[0058] In one embodiment, DSC analysis of the hydrochloride salt of the present invention shows one endothermic peak at 278.2°C.
[0059] In one embodiment, the DSC curve of the hydrochloride salt of the present invention is shown in FIG. 2B.
[0060] In one embodiment, TGA analysis of the hydrochloride salt of the present invention shows a weight loss of 0.49% at 150°C.
[0061] In one embodiment, the TGA curve of the hydrochloride salt of the present invention is shown in FIG. 2C.
[0062] The present invention further provides a process for preparing a salt of a compound of formula I, which comprises reacting a compound of formula I with hydrochloric acid in an organic solvent to obtain the hydrochloride salt of the compound of formula I.
[0063] In one embodiment, in the process for preparing the salt of the compound of formula I, the reacting molar ratio of the compound of formula I to hydrochloric acid is 1:1 to 1:2, preferably, the molar ratio is 1:1 to 1:1.1.
[0064] In one embodiment, in the process for preparing the salt of a compound of formula I, the organic solvent is toluene.
[0065] The present invention further provides a pharmaceutical composition for treating or ameliorating schizophrenia, mental retardation, mental disorder, mental retardation, mood disorder, bipolar disorder, depression, phobia, obsessive-compulsive disorder, anxiety disorder or cognitive impairment disease, comprising the hydrochloride salt and a pharmaceutical excipient.
[0066] The hydrochloride salt of the compound of formula I of the present invention has high stability and low hygroscopicity. In in vivo experiments, compared with other salts, the hydrochloride salt has higher crystallinity, smaller weight loss in TGA, a unique high endothermic signal in DSC, and a longer in vivo half-life than the base or other salts, and has obvious advantages. [Brief description of the drawings]
[0067] [Figure 1] FIG. 1 is a powder X-ray diffraction pattern (XPRD pattern) of the free base of compound of formula I according to one embodiment of the present invention. [Figure 2A] FIG. 2A is a powder X-ray diffraction pattern (XPRD pattern) of the hydrochloride salt of compound of formula I according to one embodiment of the present invention. [Figure 2B] 2B is a differential scanning calorimetry (DSC) curve of the hydrochloride salt of the compound of formula I according to one embodiment of the present invention, where the horizontal axis is temperature (° C.) and the vertical axis is heat flow (W / g). [Figure 2C] FIG. 2C is a thermogravimetric analysis curve (TGA curve) of the hydrochloride salt of the compound of formula I according to one embodiment of the present invention. [Figure 3A] FIG. 3A is a powder X-ray diffraction pattern (XPRD pattern) of the sulfate salt of compound of formula I according to one embodiment of the present invention. [Figure 3B] 3B is a differential scanning calorimetry (DSC) curve of the sulfate salt of the compound of formula I according to one embodiment of the present invention, where the horizontal axis is temperature (° C.) and the vertical axis is heat flow (W / g). [Figure 3C] FIG. 3C is a thermogravimetric analysis curve (TGA curve) of the sulfate salt of the compound of formula I according to one embodiment of the present invention. [Figure 4A] FIG. 4A is a powder X-ray diffraction pattern (XPRD pattern) of the phosphate salt of compound of formula I according to one embodiment of the present invention. [Figure 4B] 4B is a differential scanning calorimetry (DSC) curve of the phosphate salt of the compound of formula I according to one embodiment of the present invention, where the horizontal axis is temperature (° C.) and the vertical axis is heat flow (W / g). [Figure 4C] FIG. 4C is a thermogravimetric analysis curve (TGA curve) of the phosphate salt of the compound of formula I according to one embodiment of the present invention. [Figure 5A] FIG. 5A is a powder X-ray diffraction pattern (XPRD pattern) of crystalline form A of the maleate salt of compound of formula I according to one embodiment of the present invention. [Figure 5B]5B is a differential scanning calorimetry (DSC) curve of the crystalline form A of the maleate salt of compound of formula I according to one embodiment of the present invention. The horizontal axis is temperature (° C.) and the vertical axis is heat flow (W / g). [Figure 5C] FIG. 5C is a thermogravimetric analysis curve (TGA curve) of crystalline form A of the maleate salt of compound of formula I according to an embodiment of the present invention. [Figure 5D] FIG. 5D is a 1H-NMR spectrum of crystalline form A of the maleate salt of compound of formula I according to one embodiment of the present invention. [Figure 6A] FIG. 6A is a powder X-ray diffraction pattern (XPRD pattern) of the tartrate salt of compound of formula I according to one embodiment of the present invention. [Figure 6B] 6B is a differential scanning calorimetry curve (DSC curve) of the tartrate salt of the compound of formula I according to one embodiment of the present invention, in which the horizontal axis is temperature (° C.), the vertical axis is heat flow (W / g), and the thermogravimetric analysis curve (TGA curve). [Figure 7A] FIG. 7A is a powder X-ray diffraction pattern (XPRD pattern) of the fumarate salt of compound of formula I according to one embodiment of the present invention. [Figure 7B] 7B is a differential scanning calorimetry curve (DSC curve) of the fumarate salt of the compound of formula I according to one embodiment of the present invention, in which the horizontal axis is temperature (° C.), the vertical axis is heat flow (W / g) and the thermogravimetric analysis curve (TGA curve). [Figure 8A] FIG. 8A is a powder X-ray diffraction pattern (XPRD pattern) of the citrate salt of compound of formula I according to one embodiment of the present invention. [Figure 8B] 8B is a differential scanning calorimetry curve (DSC curve) of the citrate salt of the compound of formula I according to one embodiment of the present invention, the horizontal axis is temperature (° C.), the vertical axis is heat flow (W / g) and the thermogravimetric analysis curve (TGA curve). [Figure 9A] FIG. 9A is a powder X-ray diffraction pattern (XPRD pattern) of the glycolate salt of compound of formula I according to one embodiment of the present invention. [Figure 9B]9B is a differential scanning calorimetry curve (DSC curve) of the glycolate salt of the compound of formula I according to one embodiment of the present invention, in which the horizontal axis is temperature (° C.), the vertical axis is heat flow (W / g) and the thermogravimetric analysis curve (TGA curve). [Figure 10A] FIG. 10A is a powder X-ray diffraction pattern (XPRD pattern) of the malate salt of compound of formula I according to one embodiment of the present invention. [Figure 10B] 10B is a differential scanning calorimetry curve (DSC curve) of the malate salt of compound of formula I according to one embodiment of the present invention, in which the horizontal axis is temperature (° C.), the vertical axis is heat flow (W / g) and the thermogravimetric analysis curve (TGA curve). [Figure 11A] FIG. 11A is a powder X-ray diffraction pattern (XPRD pattern) of the lactate salt of compound of formula I according to one embodiment of the present invention. [Figure 11B] 11B is a differential scanning calorimetry curve (DSC curve) of the lactate salt of the compound of formula I according to one embodiment of the present invention, where the horizontal axis is temperature (° C.) and the vertical axis is heat flow (W / g) and a thermogravimetric analysis curve (TGA curve). [Figure 12A] FIG. 12A is a powder X-ray diffraction pattern (XPRD pattern) of the succinate salt of the compound of formula I according to one embodiment of the present invention. [Figure 12B] 12B is a differential scanning calorimetry curve (DSC curve) of the succinate salt of the compound of formula I according to one embodiment of the present invention. The horizontal axis is temperature (° C.), and the vertical axis is heat flow (W / g) and a thermogravimetric analysis curve (TGA curve). [Figure 13A] FIG. 13A is a powder X-ray diffraction pattern (XPRD pattern) of the adipate salt of compound of formula I according to one embodiment of the present invention. [Figure 13B] 13B is a differential scanning calorimetry curve (DSC curve) of the adipate salt of the compound of formula I according to one embodiment of the present invention, in which the horizontal axis is temperature (° C.), and the vertical axis is heat flow (W / g) and a thermogravimetric analysis curve (TGA curve). [Figure 14A] FIG. 14A is a powder X-ray diffraction pattern (XPRD pattern) of the p-toluenesulfonic acid salt of compound of formula I according to one embodiment of the present invention. [Figure 14B]14B is a differential scanning calorimetry curve (DSC curve) of the p-toluenesulfonate salt of the compound of formula I according to one embodiment of the present invention, in which the horizontal axis is temperature (° C.), and the vertical axis is heat flow (W / g) and a thermogravimetric analysis curve (TGA curve). [Figure 15A] FIG. 15A is a powder X-ray diffraction pattern (XPRD pattern) of the methanesulfonate salt of compound of formula I according to one embodiment of the present invention. [Figure 15B] 15B is a differential scanning calorimetry curve (DSC curve) of the methanesulfonate salt of the compound of formula I according to one embodiment of the present invention. The horizontal axis is temperature (° C.), and the vertical axis is heat flow (W / g) and a thermogravimetric analysis curve (TGA curve). [Figure 16A] FIG. 16A is a powder X-ray diffraction pattern (XPRD pattern) of the hydrobromide salt of compound of formula I according to one embodiment of the present invention. [Figure 16B] 16B is a differential scanning calorimetry curve (DSC curve) of the hydrobromide salt of the compound of formula I according to one embodiment of the present invention. The horizontal axis is temperature (° C.), and the vertical axis is heat flow (W / g) and a thermogravimetric analysis curve (TGA curve). [Figure 17A] FIG. 17A is a powder X-ray diffraction pattern (XPRD pattern) of crystalline form B of the maleate salt of compound of formula I according to one embodiment of the present invention. [Figure 17B] 17B is a differential scanning calorimetry curve (DSC curve) of the crystalline form B of the maleate salt of compound of formula I according to one embodiment of the present invention. The horizontal axis is temperature (° C.), and the vertical axis is heat flow (W / g) and a thermogravimetric analysis curve (TGA curve). [Figure 17C] FIG. 17C is an XRPD pattern of crystalline form B of the maleate salt of compound of formula I according to an embodiment of the present invention before and after heating. [Figure 18A] FIG. 18A is an individual blood drug concentration-time curve after intragastric administration of 1 mg / kg of the compound of formula I to a rat. [Figure 18B] FIG. 18B is an individual blood drug concentration-time curve after intragastric administration of 1 mg / kg of the sulfate salt of the compound of formula I to rats. [Figure 18C]FIG. 18C is an individual blood drug concentration-time curve after intragastric administration of 1 mg / kg of the hydrochloride salt of the compound of formula I to a rat. [Figure 18D] FIG. 18D is an individual blood drug concentration-time curve after intragastric administration of 1 mg / kg of the phosphate salt of the compound of formula I to rats. [Figure 18E] FIG. 18E is an individual blood drug concentration-time curve after intragastric administration of 1 mg / kg of the maleate salt of the compound of formula I to rats. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0068] The present invention will now be further described with reference to examples. Note that these examples are merely illustrative and do not limit the present invention. If a person skilled in the art makes various modifications or adjustments based on the spirit of the present invention, all of these modifications or adjustments are within the scope of protection of the present invention.
[0069] The present invention N'-[trans-4-[2-[4-(benzo[b]thiophen-7-yl)piperazin-1-yl]ethyl]cyclohexyl]-N,N-dimethylurea The powder X-ray diffraction patterns of the crystalline forms of various salts are shown as the positions of the diffraction peaks (diffraction angles 2θ (°)), the interplanar spacing d (Å), and the relative intensities of the diffraction peaks (I / I0).
[0070] The term "relative intensity" refers to the ratio of the intensity of a peak to the intensity of the highest peak among all diffraction peaks in a powder X-ray diffraction pattern, where the intensity of the highest peak is taken as 100%.
[0071] The term "substantially identical" means that at least 70%, at least 80%, at least 90%, at least 95%, or at least 99% of the peaks in an X-ray powder diffraction pattern are seen in an exemplary X-ray powder diffraction pattern.
[0072] (Example) Reagents: The reactants and catalysts used in the examples of the present invention are all chemically pure and can be used directly or can be easily purified as required. The organic solvents and the like are all analytical grade and can be used directly. All reagents are purchased from China National Pharmaceutical (Group) Shanghai Chemical Reagent Company.
[0073] The amorphous form of the compound of formula I may be prepared by, but is not limited to, the method described in Example 5 of the prior art (eg, CN106518841A).
[0074] Powder X-ray diffraction: Powder X-ray diffraction analysis was performed using CuKα radiation on a PANalytacal powder X-ray diffractometer. The test power was 45 kV × 40 mA, the step width was 0.02°, and the scanning range was 3–40° (2θ) with θ–2θ continuous measurement.
[0075] Differential Scanning Calorimetry (DSC): The measurements were performed using a TA Q2000 / 2500 differential scanning calorimeter under the following conditions: protective gas was nitrogen, the heating rate was 10° C. / min, and the temperature was gradually increased from 25° C. to the set end point.
[0076] Thermogravimetric analysis (TGA): The measurements were performed using a TA Q5000 / 5500 thermogravimetric analyzer with nitrogen as protective gas, a heating rate of 10° C. / min, and the temperature was gradually increased from room temperature to the set end point.
[0077] Content detection (HPLC): [Table 1]
[0078] Solution preparation: Diluent (blank solution): acetonitrile / water = 1 / 1 (V / V) Sample solution: Accurately weigh out 5 mg of sample and place in a 10 mL measuring flask. Add 2 mL of methanol to dissolve, then add diluent (blank solution) to volume and mix uniformly to complete.
[0079] [Table 2]
[0080] Example 1: N'-[trans-4-[2-[4-(benzo[b]thiophen-7-yl)piperazin-1-yl]ethyl]cyclohexyl]-N,N-dimethylurea Preparation and Identification of Crystalline Form A of the Free Base of Compound of Formula I The free base was prepared with reference to Example 5 of CN106518841A.
[0081] Preparation of 1-benzo[b]thiophene-4-piperazine hydrochloride [ka] A mixture of 7.20 g of 7-bromobenzo[b]thiophene, 19.9 g of anhydrous piperazine, 4.70 g of sodium t-butoxide, 0.32 g of (R)-(+)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP), 0.63 g of tris(dibenzylideneacetone)dipalladium and 150 mL of toluene was refluxed for 1 hour under nitrogen atmosphere. The reaction solution was added with 150 mL of water, then extracted with ethyl acetate (100 mL x 3), washed with water, dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure (0.01 MPa, 45 °C). The residue was extracted by silica gel column chromatography (dichloromethane:methanol:25% ammonium hydroxide = 100:10:1) to obtain 4.60 g of yellow oil, 1-benzo[b]thiophen-4-yl-piperazine. To a methanol solution (25 mL) containing 4.6 g of 1-benzo[b]thiophen-4-yl-piperazine, 2 mL of concentrated hydrochloric acid was added, and the solvent was evaporated under reduced pressure (0.01 MPa, 45° C.). Ethyl acetate (50 mL) was added to the residue, and the crystalline precipitate was filtered and dissolved in 15 mL of methanol by refluxing, then cooled to room temperature (25° C.) and recrystallized to obtain colorless needle-like crystals, 1-benzo[b]thiophen-4-yl-piperazine hydrochloride.
[0082] Preparation of trans-4-[2-[7-(benzo[b]thiophene)-7-piperazinyl]ethyl]cyclohexyl-t-butylcarbamate [ka] 2.54g (10mmol) of 1-benzo[b]thiophene-4-piperazine hydrochloride and 2.40g (10mmol) of trans-2-{1-[4-(Nt-butoxycarbonyl)amino]cyclohexyl}-acetaldehyde were dissolved in 120mL of dichloromethane, and 1.40mL (10mmol) of triethylamine was added at room temperature (25℃±2℃) and stirred slowly for 10 minutes. Then, 3.16g (14.8mmol) of sodium triacetoxyborohydride was added little by little, and the mixture was allowed to react for 24 hours with stirring at room temperature. After the reaction was completed, 120mL of 10% sodium bicarbonate solution was added. The reaction mixture was directly extracted and separated, the organic phase was dried over anhydrous sodium sulfate, and finally filtered and rotary evaporated until no liquid remained. The solid was dissolved by refluxing with 15 mL of ethyl acetate, cooled to room temperature (25°C ± 2°C), and crystallized to obtain 3.70 g of the desired product.
[0083] Preparation of trans-4-[2-[7-(benzo[b]thiophene)-7-piperazinyl]ethyl]cyclohexylamine [ka] In an ice-water bath, 4.43 g of trans-4-[2-[7-(benzo[b]thiophene)-7-piperazinyl]ethyl]cyclohexyl-t-butylcarbamate was placed in a reaction flask, 80 mL of saturated hydrogen chloride in ethyl acetate was added, and the mixture was stirred for 8 hours to carry out the deprotection reaction, and finally a white precipitate was formed, giving 3.42 g of the hydrochloride salt of the title compound. 50 mL of dichloromethane solution and 50 mL of saturated sodium bicarbonate solution were added to the solid, and the mixture was stirred for 30 minutes, followed by separation and extraction, and the organic phase was concentrated (0.01 MPa, 40°C) to give 3.30 g of the target product.
[0084] N'-[trans-4-[2-[4-(benzo[b]thiophen-7-yl)piperazin-1-yl]ethyl]cyclohexyl]-N,N-dimethylurea Preparation of [ka] 1.73g of trans-4-[2-[7-(benzo[b]thiophene)-7-piperazinyl]ethyl]cyclohexylamine was dissolved in 50mL of dichloromethane, and 1.40mL of triethylamine and 5.50mmol of N,N-dimethylcarbamoyl chloride were added. The mixture was stirred at room temperature (25℃±2℃) for 48 hours. After the reaction was completed, 50mL of water was added to extract and separate the liquids, and the organic phase was concentrated (0.01MPa, 45℃), and the target component was collected by column chromatography (400 mesh silica gel) with methanol:dichloromethane=1:10, and concentrated to obtain 1.89g of the target product in amorphous form.
[0085] Preparation and identification of crystalline form A of the free base: 200 mg of the amorphous product was dissolved in ethyl acetate, refluxed at 77°C to clarify, cooled to room temperature (20-25°C), stirred for 1 hour, suction filtered, and recrystallized to obtain a crystalline form, which was named as crystalline form A of the free base of the compound of formula I, and its X-ray diffraction pattern (XRPD) is shown in Figure 1, and the solubility of crystalline form A of the free base in water was about 0.031 mg / mL.
[0086] Example 2: N'-[trans-4-[2-[4-(benzo[b]thiophen-7-yl)piperazin-1-yl]ethyl]cyclohexyl]-N,N-dimethylurea Preparation and Characterization of the Hydrochloride Salt of (Compound of Formula I) Preparation of salt: 200 mg of the free base product of Example 1 and hydrochloric acid in a molar ratio of 1.05 were mixed in toluene at room temperature and stirred for 3 days, and then dried in vacuum at 50° C. for 3 days to obtain a crystalline form, which is named as Form B of the hydrochloride salt of the compound of formula I.
[0087] FIG. 2A shows the powder X-ray diffraction pattern (XRPD), and Table 1 shows the characteristic peaks with lattice spacing (Å) corresponding to 2θ. [Table 3]
[0088] For crystalline form B of the hydrochloride salt of compound of Formula I, the solubility in water is greater than 4.6 mg / mL, the sample exhibits one endothermic peak at 278.2° C. as shown in the DSC results in FIG. 2B, and the sample exhibits a weight loss of 0.49% when heated to 150° C. as shown in the TGA results in FIG. 2C. The HPLC / IC measurements are consistent with a stoichiometric ratio of 1:1 (base:hydrochloric acid).
[0089] Example 3: N'-[trans-4-[2-[4-(benzo[b]thiophen-7-yl)piperazin-1-yl]ethyl]cyclohexyl]-N,N-dimethylurea Preparation and Characterization of the Sulfate Salt of (Compound of Formula I) Preparation of sulfate salt (a): 200 mg of the product of Example 1 was mixed with sulfuric acid in ethyl acetate (EtOAc) at room temperature by rotary mixing for 4 days, and then dried under vacuum at 50° C. for 3 days to obtain a crystalline form, which is designated as Form A of the sulfate salt of the compound of formula I.
[0090] FIG. 3A shows the powder X-ray diffraction pattern (XRPD), and Table 2 shows the characteristic peaks with lattice spacing (Å) corresponding to 2θ. [Table 4]
[0091] For crystalline form A of the sulfate salt of compound of Formula I, the solubility in water is greater than 8.0 mg / mL, the sample exhibits one endothermic peak at 195.1° C. as shown in the DSC results in FIG. 3B, and the sample exhibits a weight loss of 0.43% when heated to 150° C. as shown in the TGA results in FIG. 3C. The HPLC / IC results are consistent with a 1:1 (base:sulfuric acid) stoichiometry.
[0092] Preparation of sulfate (b): 200 mg of the product of Example 1 and sulfuric acid in a molar ratio of 1.05 were mixed in isopropylamine (IPA) by rotary mixing at room temperature for 4 days, and then dried in vacuum at 50° C. for 3 days to obtain a crystalline form having an X-ray diffraction pattern (XRPD), DSC curve and TGA curve substantially identical to those of crystalline form A of the sulfate salt of the compound of formula I.
[0093] Preparation of sulfate (c): 200 mg of the product of Example 1 and sulfuric acid in a molar ratio of 1.05 were mixed in acetonitrile (ACN) by rotary mixing at room temperature for 4 days, and then dried under vacuum at 50° C. for 3 days to obtain a crystalline form having an X-ray diffraction pattern (XRPD), DSC curve and TGA curve substantially identical to those of crystalline form A of the sulfate salt of the compound of formula I.
[0094] Preparation of sulfate (d): 200 mg of the product of Example 1 and sulfuric acid in a molar ratio of 1.05 were mixed in toluene (Toluene) by rotary mixing at room temperature for 4 days, and then dried in vacuum at 50° C. for 3 days to obtain a crystalline form having an X-ray diffraction pattern (XRPD), DSC curve and TGA curve substantially identical to those of the crystalline form A of the sulfate salt of the compound of formula I.
[0095] Example 4: N'-[trans-4-[2-[4-(benzo[b]thiophen-7-yl)piperazin-1-yl]ethyl]cyclohexyl]-N,N-dimethylurea Preparation and Characterization of the Phosphate Salt of (Compound of Formula I) Preparation of phosphate salt (a): 200 mg of the product of Example 1 and phosphoric acid in a molar ratio of 1.05 in ethyl acetate (EtOAc) were mixed by rotation at room temperature and stirred for 5 days to obtain a crystalline form, designated as Form A of the phosphate salt of the compound of formula I.
[0096] FIG. 4A shows the powder X-ray diffraction pattern (XRPD), and Table 3 shows the characteristic peaks with lattice spacing (Å) corresponding to 2θ. [Table 5]
[0097] For crystalline form A of the phosphate salt of compound of Formula I, the solubility in water is greater than 7.6 mg / mL, the sample exhibits one endothermic peak at 213.9° C. as shown in the DSC results in FIG. 4B, and the sample exhibits a weight loss of 0.7% when heated to 150° C. as shown in the TGA results in FIG. 4C. The HPLC / IC measurements are consistent with a 1:1 (base:phosphate) stoichiometry.
[0098] Preparation of phosphate (b): 200 mg of the product of Example 1 and phosphoric acid in a molar ratio of 1.05 were mixed in isopropylamine (IPA) and stirred at room temperature for 5 days to obtain a crystalline form having an X-ray diffraction pattern (XRPD), DSC curve and TGA curve substantially identical to those of the crystalline form A of the phosphate of the compound of formula I.
[0099] Preparation of phosphate (c): 200 mg of the product of Example 1 and phosphoric acid in a molar ratio of 1.05 were mixed in acetone at room temperature and stirred for 5 days to obtain a crystalline form, which had substantially the same X-ray diffraction pattern (XRPD), DSC curve and TGA curve as those of the crystalline form A of the phosphate of the compound of formula I.
[0100] Preparation of phosphate (d): 200 mg of the product of Example 1 and phosphoric acid in a molar ratio of 1.05 were mixed in acetonitrile (ACN) by rotary mixing at room temperature for 5 days to obtain a crystalline form, which was substantially identical in X-ray diffraction pattern (XRPD), DSC curve and TGA curve to those of the crystalline form A of the phosphate of the compound of formula I.
[0101] Preparation of phosphate (e): 200 mg of the product of Example 1 and phosphoric acid in a molar ratio of 1.05 were mixed in toluene (Toluene) by rotary mixing at room temperature for 5 days to obtain a crystalline form, which was substantially identical in X-ray diffraction pattern (XRPD), DSC curve and TGA curve to those of the crystalline form A of the phosphate of the compound of formula I.
[0102] Example 5: N'-[trans-4-[2-[4-(benzo[b]thiophen-7-yl)piperazin-1-yl]ethyl]cyclohexyl]-N,N-dimethylurea Preparation and Characterization of the Maleate Salt of Formula I Preparation of maleate salt (a): 200 mg of the product of Example 1 and maleic acid in a molar ratio of 1.05 were mixed in acetone at room temperature and stirred for 5 days to obtain a crystalline form, which is named as Form A of the maleate salt of the compound of formula I.
[0103] FIG. 5A shows the powder X-ray diffraction pattern (XRPD), and Table 4 shows the characteristic peaks with lattice spacing (Å) corresponding to 2θ. [Table 6]
[0104] For the crystalline form A of the maleate salt of the compound of formula I, the solubility in water was greater than 2.6 mg / mL, and the sample showed one endothermic peak at 191.8° C. as shown in the DSC results in FIG. 5B, and the sample showed a weight loss of 0.41% when heated to 150° C. as shown in the TGA results in FIG. 5C. 1 H-NMR results are consistent with a 1:1 (base:maleic acid) stoichiometry.
[0105] Preparation of maleate salt (b): 200 mg of the product of Example 1 and maleic acid in a molar ratio of 1.05 were mixed in isopropylamine (IPA) by rotary mixing at room temperature for 5 days to obtain a crystalline form, which was substantially identical in X-ray diffraction pattern (XRPD), DSC curve and TGA curve to those of the crystalline form A of the maleate salt of the compound of formula I.
[0106] Preparation of maleate salt (c): 200 mg of the product of Example 1 and maleic acid in a molar ratio of 1.05 were mixed in ethyl acetate (EtOAc) and stirred at room temperature for 5 days to obtain a crystalline form having substantially the same X-ray diffraction pattern (XRPD), DSC curve and TGA curve as those of the crystalline form A of the maleate salt of the compound of formula I.
[0107] Preparation of maleate salt (d): 200 mg of the product of Example 1 and maleic acid in a molar ratio of 1.05 were mixed in acetonitrile (ACN) by rotary mixing at room temperature for 5 days to obtain a crystalline form, which was substantially identical in X-ray diffraction pattern (XRPD), DSC curve and TGA curve to those of the crystalline form A of the maleate salt of the compound of formula I.
[0108] Preparation of maleate (e): 200 mg of the product of Example 1 and maleic acid in a molar ratio of 1.05 were mixed in toluene and stirred at room temperature for 5 days to obtain a crystalline form having substantially the same X-ray diffraction pattern (XRPD), DSC curve and TGA curve as those of the crystalline form A of the maleate of the compound of formula I.
[0109] Comparative Example 1: N'-[trans-4-[2-[4-(benzo[b]thiophen-7-yl)piperazin-1-yl]ethyl]cyclohexyl]-N,N-dimethylurea Preparation and Characterization of the Tartrate Salt of Formula I Preparation of tartrate salt: 200 mg of the product of Example 1 and tartaric acid in a molar ratio of 1 were stirred in acetone at room temperature for 5 days. The crystalline form was named as Form A of the tartrate salt of the compound of formula I.
[0110] For crystalline form A of the tartrate salt of compound of formula I, FIG. 6A shows the X-ray powder diffraction pattern (XRPD), and as shown in the DSC result in FIG. 6B, the sample showed one endothermic peak at 169.8° C., and as shown in the TGA result in FIG. 6B, the sample showed a weight loss of 5.5% when heated to 150° C. 1 H-NMR results are consistent with a 1:1 (base:tartaric acid) stoichiometry.
[0111] Comparative Example 2: N'-[trans-4-[2-[4-(benzo[b]thiophen-7-yl)piperazin-1-yl]ethyl]cyclohexyl]-N,N-dimethylurea Preparation and Characterization of the Fumarate Salt of Formula I Preparation of fumarate salt: 200 mg of the product of Example 1 and fumaric acid in a molar ratio of 1 were stirred in acetone at room temperature for 5 days. The resulting crystalline form is designated as Form A of the fumarate salt of the compound of formula I.
[0112] For crystalline form A of the fumarate salt of compound of formula I, FIG. 7A shows the X-ray powder diffraction pattern (XRPD), and as shown in the DSC result in FIG. 7B, the sample showed one endothermic peak at 200.3° C., and as shown in the TGA result in FIG. 7B, the sample showed a weight loss of 0.9% when heated to 150° C. 1 H-NMR results are consistent with a 1:1 (base:fumaric acid) stoichiometry.
[0113] Comparative Example 3: N'-[trans-4-[2-[4-(benzo[b]thiophen-7-yl)piperazin-1-yl]ethyl]cyclohexyl]-N,N-dimethylurea Preparation and Characterization of the Citrate Salt of Formula I Preparation of citrate salt: 200 mg of the product of Example 1 and citric acid in a molar ratio of 1 in ethyl acetate (EtOAc) were stirred at room temperature for 5 days. The crystalline form was designated as Form A of the citrate salt of the compound of formula I.
[0114] For crystalline form A of the citrate salt of the compound of Formula I, FIG. 8A shows the X-ray powder diffraction pattern (XRPD), and as shown in the DSC result in FIG. 8B, the sample showed one endothermic peak at 126.8° C., and as shown in the TGA result in FIG. 8B, the sample showed a weight loss of 2.6% when heated to 140° C. 1 H-NMR results are consistent with a 1:1 (base:citric acid) stoichiometry.
[0115] Comparative Example 4: N'-[trans-4-[2-[4-(benzo[b]thiophen-7-yl)piperazin-1-yl]ethyl]cyclohexyl]-N,N-dimethylurea Preparation and Characterization of the Glycolic Acid Salt of (Compound of Formula I) Preparation of glycolate salt: 200 mg of the product of Example 1 and glycolic acid in a molar ratio of 1 were stirred with isopropylamine (IPA) at room temperature for 5 days to obtain a crystalline form, designated as Form A of the glycolate salt of compound of formula I.
[0116] For crystalline form A of the glycolate salt of compound of formula I, FIG. 9A shows the X-ray powder diffraction pattern (XRPD), and as shown in the DSC result in FIG. 9B, the sample showed one endothermic peak at 129.2° C., and as shown in the TGA result in FIG. 9B, the sample showed a weight loss of 11.9% when heated to 120° C. 1 H-NMR results are consistent with a 1:1 (base:glycolic acid) stoichiometry.
[0117] Comparative Example 5: N'-[trans-4-[2-[4-(benzo[b]thiophen-7-yl)piperazin-1-yl]ethyl]cyclohexyl]-N,N-dimethylurea Preparation and Characterization of the Malate Salt of Formula I Preparation of malate: 200 mg of the product of Example 1 and L-malic acid in a molar ratio of 1 were stirred in acetone at room temperature for 5 days. The resulting crystalline form is designated as Form A of the malate of compound of formula I.
[0118] For crystalline form A of the malate salt of compound of formula I, FIG. 10A shows the X-ray powder diffraction pattern (XRPD), and as shown in the DSC result in FIG. 10B, the sample exhibited two endothermic peaks at 140.4° C. and 155.0° C., and as shown in the TGA result in FIG. 10B, the sample exhibited a weight loss of 8.8% when heated to 140° C. 1H-NMR results are consistent with a 1:1 (base:malic acid) stoichiometry.
[0119] Comparative Example 6: N'-[trans-4-[2-[4-(benzo[b]thiophen-7-yl)piperazin-1-yl]ethyl]cyclohexyl]-N,N-dimethylurea Preparation and Characterization of the DL-Lactate Salt of Formula I Preparation of lactate salt: 200 mg of the product of Example 1 and DL-lactic acid in a molar ratio of 1 in ethyl acetate (EtOAc) were stirred at room temperature for 5 days to obtain a crystalline form, designated as Form A of the lactate salt of the compound of formula I.
[0120] For crystalline form A of the lactate salt of the compound of Formula I, FIG. 11A shows the X-ray powder diffraction pattern (XRPD), and as shown in the DSC results in FIG. 11B, the sample exhibited one endothermic peak at 106.9° C., and as shown in the TGA results in FIG. 11B, the sample exhibited a weight loss of 1.7% when heated to 100° C. 1 H-NMR results are consistent with a 1:1 (base:lactic acid) stoichiometry.
[0121] Comparative Example 7: N'-[trans-4-[2-[4-(benzo[b]thiophen-7-yl)piperazin-1-yl]ethyl]cyclohexyl]-N,N-dimethylurea Preparation and Characterization of the Succinate Salt of Formula I Preparation of succinate salt: 200 mg of the product of Example 1 and succinic acid in a molar ratio of 1 in ethyl acetate (EtOAc) were stirred at room temperature for 5 days. The crystalline form was named as Form A of the succinate salt of the compound of formula I.
[0122] For crystalline form A of the succinate salt of the compound of formula I, FIG. 12A shows the X-ray powder diffraction pattern (XRPD), and as shown in the DSC result in FIG. 12B, the sample showed one endothermic peak at 152.0° C., and as shown in the TGA result in FIG. 12B, the sample showed a weight loss of 2.3% when heated to 150° C. 1 H-NMR results are consistent with a 1:1 (base:succinic acid) stoichiometry.
[0123] Comparative Example 8: N'-[trans-4-[2-[4-(benzo[b]thiophen-7-yl)piperazin-1-yl]ethyl]cyclohexyl]-N,N-dimethylurea Preparation and Characterization of the Adipate Salt of Formula I Preparation of adipate salt: 200 mg of the product of Example 1 and adipic acid in a molar ratio of 1 in ethyl acetate (EtOAc) were stirred at room temperature for 5 days. The crystalline form was named as Form A of the adipate salt of the compound of formula I.
[0124] For crystalline form A of the adipate salt of compound of Formula I, FIG. 13A shows the X-ray powder diffraction pattern (XRPD); as shown in FIG. 13B, the TGA result shows that the sample lost 1.0% weight when heated to 150° C.; and as shown in FIG. 13B, the DSC result shows that the sample had one endothermic peak at 115.0° C. 1 H-NMR results are consistent with a 1:1 (base:adipic acid) stoichiometry.
[0125] Comparative Example 9: N'-[trans-4-[2-[4-(benzo[b]thiophen-7-yl)piperazin-1-yl]ethyl]cyclohexyl]-N,N-dimethylurea Preparation and Characterization of the p-Toluenesulfonic Acid Salt of (Compound of Formula I) Preparation of p-toluenesulfonic acid salt: 200 mg of the product of Example 1 and p-toluenesulfonic acid in a molar ratio of 1 in ethyl acetate (EtOAc) were stirred at room temperature for 5 days to obtain a crystalline form, which is designated as Form A of the p-toluenesulfonic acid salt of the compound of formula I.
[0126] For crystalline form A of the p-toluenesulfonate salt of compound of formula I, FIG. 14A shows the X-ray powder diffraction pattern (XRPD), and as shown in the DSC result in FIG. 14B, the sample showed one endothermic peak at 205.6° C., and as shown in the TGA result in FIG. 14B, the sample showed a weight loss of 0.8% when heated to 150° C. 1 H-NMR results are consistent with a 1:1 (base:p-toluenesulfonic acid) stoichiometry.
[0127] Comparative Example 10: N'-[trans-4-[2-[4-(benzo[b]thiophen-7-yl)piperazin-1-yl]ethyl]cyclohexyl]-N,N-dimethylurea Preparation and Characterization of the Methanesulfonate Salt of Formula I Preparation of methanesulfonate salt: 200 mg of the product of Example 1 and methanesulfonic acid in a molar ratio of 1 in isopropylamine (IPA) were stirred at room temperature for 5 days to obtain a crystalline form, designated as Form A of the methanesulfonate salt of the compound of formula I.
[0128] For crystalline form A of the methanesulfonate salt of compound of Formula I, FIG. 15A shows the X-ray powder diffraction pattern (XRPD), and as shown in the DSC result in FIG. 15B, the sample showed one endothermic peak at 211.1° C., and as shown in the TGA result in FIG. 15B, the sample showed a weight loss of 3.0% when heated to 150° C. 1 H-NMR results are consistent with a 1:1 (base:methanesulfonic acid) stoichiometry.
[0129] Comparative Example 11: N'-[trans-4-[2-[4-(benzo[b]thiophen-7-yl)piperazin-1-yl]ethyl]cyclohexyl]-N,N-dimethylurea Preparation and Characterization of the Hydrobromide Salt of (Compound of Formula I) Preparation of hydrobromide salt: 200 mg of the product of Example 1 and hydrobromic acid in a molar ratio of 1 in ethyl acetate (EtOAc) were stirred at room temperature for 5 days. The crystalline form was named as Form A of the hydrobromide salt of the compound of formula I.
[0130] For crystalline form A of the hydrobromide salt of compound of Formula I, FIG. 16A shows the X-ray powder diffraction pattern (XRPD), and as shown in the DSC result in FIG. 16B, the sample showed one endothermic peak at 249.6° C., and as shown in the TGA result in FIG. 16B, the sample showed a weight loss of 1.4% when heated to 150° C. 1 H-NMR results are consistent with a 1:1 (base:hydrobromic acid) stoichiometry.
[0131] Analysis of the XRPD patterns, DSC curves and TGA curves of the salts and crystalline forms showed high crystallinity, low weight loss in TGA, and unique high endothermic signal in DSC, and in consideration of the safety of the acids, the hydrochloride, sulfate, phosphate and maleate salts of the compound of formula I are preferred.
[0132] Comparative Example 12: N'-[trans-4-[2-[4-(benzo[b]thiophen-7-yl)piperazin-1-yl]ethyl]cyclohexyl]-N,N-dimethylurea Preparation and Characterization of the Maleate Salt of Formula I Preparation of maleate salt: Antisolvent was added to 200 mg of the product of Example 1 in CHCl3 / IPAc (chloroform / isopropyl acetate) system to obtain a crystalline form, which is named as crystalline form B of the maleate salt of compound of formula I.
[0133] FIG. 17A shows the X-ray powder diffraction pattern (XRPD).
[0134] The X-ray powder diffraction pattern (XRPD) of crystalline form B of the maleate salt of compound of Formula I is shown, and the DSC results in FIG. 17B show that the sample exhibited two endothermic peaks at 138.8° C. and 193.6° C., and the TGA results in FIG. 17B show that the sample exhibited a weight loss of 4.7% when heated to 90° C., and subsequently heated to 150° C., the sample exhibited a weight loss of 17.8%. 1 H-NMR results were consistent with a 1:1 (base:maleic acid) stoichiometry, and crystalline form B of the maleate salt was converted to crystalline form A after heating to 150° C. and cooling to room temperature. The results are shown in FIG. 17C.
[0135] Compared to the maleate's crystalline form A, crystalline form B undergoes a crystal transformation when heated to become crystalline form A. It is less stable than crystalline form A.
[0136] Example 6: Hygroscopicity (DVS) test Dynamic moisture sorption curves were measured using DVS Intrinsic from SMS (Surface Measurement Systems).
[0137] 20 mg of samples of the crystalline forms of the Examples and Comparative Examples were placed in an environment of 25° C. / 80% relative humidity and subjected to dynamic moisture sorption (DVS) measurement. The results of measurement by HPLC are shown in Table 5. [Table 7]
[0138] As can be seen from the above results, within one week, the hydrochloride, sulfate, phosphate, and maleate salts showed little or no hygroscopicity, while the maleate salt showed low hygroscopicity compared to the other salts.
[0139] Example 7: In this study, the absorption and characteristics of the free base and four salts (sulfate, hydrochloride, phosphate, maleate) of the compound of formula I in rats were initially studied. A pharmacokinetic study was carried out in SD rats by single intragastric administration of 1 mg / kg of the compound of formula I and the four salts (calculating the salt form based on the concentration of the base).
[0140] Testing Method: The free base of Example 1 and four salts (including the hydrochloride of Example 2, the sulfate of Example 3, the phosphate of Example 4 and the maleate of Example 5) were each administered intragastrically at 1 mg / kg to SD rats. Each group consisted of four male rats. The plasma concentration of the compound of formula I was measured, and the pharmacokinetic parameters were calculated according to the concentration-time curve, and the results in Table 6 were obtained. [Table 8]
[0141] As can be seen from Table 6, the maleate salt had a longer half-life, extended duration of action in vivo, and was more bioavailable than the other salts.
[0142] Example 8: In vivo interindividual analysis of the compound of formula I and its salts 1. Materials and Methods 1.1 Drugs The compound of formula I and its salts (sulfate, hydrochloride, phosphate, maleate) are provided by Shanghai Jingneochemical Pharmaceutical Co., Ltd. 1.2 Experimental animals Animal species: SD rat, sex: male, weight: approximately 250 g, provided by Shanghai Jieshijie Experimental Materials Co., Ltd. 1.3 Test Method 1.3.1 Method of administration Route: Single intragastric administration, Dose: Calculated at 10mL / kg body weight Preparation: Weigh out the appropriate amount of free base or salt of the compound of formula I, add a small amount of 0.5% CMC-Na, grind, and add 0.5% CMC-Na to the required volume. The concentration was calculated with the base. 1.3.2 Dosing and sample collection 20 SD rats were divided into 5 groups, each with 4 rats. They were fasted for 12 hours before administration, and drinking water was not restricted. A single dose of the compound or salt of formula I was administered intragastrically at a dose of 1 mg / kg. Approximately 100 μL of blood was collected from the orbital venous plexus before administration, 5 minutes, 10 minutes, 20 minutes, 0.5 hours, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, and 36 hours after administration. The blood was anticoagulated with 1% heparin, centrifuged at 8000 rpm for 4 minutes, and then plasma was separated. It was stored at -40°C. 1.4 Plasma sample measurement method LC-MS / MS method. 1.5 Data Processing The pharmacokinetic parameters after administration to rats were calculated using the non-compartmental model of DAS2.0 software.
[0143] 2 Results After a single intragastric administration of 1 mg / kg of the compound or salt of formula I to rats, the individual blood drug concentrations and the average blood drug concentration-time curves are shown in Table 7(a) to Table 7(e) and Figure 18A to Figure 18E, respectively. Compared with the other salts, the maleate salt showed the smallest individual variability. The small individual variability is of great significance for clinical treatment, since it can avoid the instability of the effect in clinical use. [Table 9] [Table 10] [Table 11] [Table 12] [Table 13] [Prior art documents] [Patent documents]
[0144]
Patent Document 1
Claims
1.
1. wherein, in a powder X-ray diffraction pattern expressed in 2θ angles using CuKα radiation, diffraction peaks are observed at at least 11.804°±0.2°, 12.703°±0.2°, 13.493°±0.2°, 14.495°±0.2°, 15.096°±0.2°, 17.108°±0.2°, 19.104°±0.2°, 19.655°±0.2°, 20.023°±0.2°, 21.611°±0.2°, and 24.088°±0.2°.
2. The crystal according to claim 1, further comprising diffraction peaks at 2θ values of 7.246°±0.2°, 17.567°±0.2°, 18.794°±0.2°, 20.395°±0.2°, 21.030°±0.2°, 22.496°±0.2°, 24.867°±0.2° and 26.412°±0.2°.
3. The crystal according to claim 2, further characterized in that diffraction peaks are observed at 2θ values of 11.045°±0.2°, 22.997°±0.2°, 25.336°±0.2°, 27.786°±0.2°, 28.292°±0.2°, 28.914°±0.2°, 29.804°±0.2°, 30.770°±0.2°, 31.628°±0.2° and 33.952°±0.2°.
4. The crystal according to claim 1, characterized in that an endothermic peak is observed at 191.8°C in DSC analysis.
5. The crystal of claim 1, having an XRPD pattern as shown in Figure 5A.
6. The crystal according to claim 4, having a DSC curve as shown in FIG. 5B.
7. The crystal according to claim 1, characterized in that a weight loss of 0.41% at 150°C is observed by TGA analysis.
8. The crystal according to claim 7, having a TGA curve as shown in FIG. 5C.
9. A method for producing the crystal according to any one of claims 1 to 8, comprising reacting a compound of N'-[trans-4-[2-[4-(benzo[b]thiophen-7-yl)piperazin-1-yl]ethyl]cyclohexyl]-N,N-dimethylurea with maleic acid in an organic solvent to obtain a compound of formula II.
10. A pharmaceutical composition for treating or ameliorating schizophrenia, mental retardation, mental disorder, mental retardation, mood disorder, bipolar disorder, depression, phobia, obsessive-compulsive disorder, anxiety disorder or cognitive impairment, comprising the crystal according to any one of claims 1 to 8 and a pharmaceutical excipient.
Citation Information
Patent Citations
Cyclohexane derivative or stereoisomer or salt and preparation and application thereof
CN106518841A
Cyclohexane derivative or stereoisomer or salt thereof, and preparation and use thereof
WO2017045599A1
